Compare Alcon AG (ALC) vs Upstart Holdings Inc (UPST) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alcon AG vs Upstart Holdings Inc — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while Upstart Holdings Inc trades at $31.89 (market cap $3.16B). The key difference: Alcon AG is far larger — about 10.3× Upstart Holdings Inc's market cap, and Alcon AG pays a 0.54% dividend while Upstart Holdings Inc pays none. Which is the better fit depends on your goals.
| ALC | UPST | |
|---|---|---|
Market Cap | $32.69B | $3.16B |
Sector | Health | Financials |
52-Week High | $92.22 | $84.13 |
52-Week Low | $62.02 | $24.22 |
Enterprise Value | $36.28B | — |
Dividend Yield | 0.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Upstart trades at $33.06, down 4.95% today, with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported $1.02B revenue in 2025 with net income of $53.60M, marking a return to profitability after previous losses. Recent news highlights AI lending growth and a $600M funding deal with Neuberger (Business Wire, June 24, 2026).
Outlook is cautiously optimistic with a consensus price target of $43.00 (45% buy ratings), but risks include volatile cash flows, high debt-to-asset ratio of 61.48%, and execution challenges in expanding auto/home lending products. The stock offers upside if AI-driven originations sustain growth, yet remains sensitive to funding and macroeconomic conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alcon AG
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →About Upstart Holdings Inc
Upstart Holdings Inc provides credit services. The company provides a proprietary, cloud-based, artificial intelligence lending platform. The platform aggregates consumer demand for loans and connects it to the network of Upstart AI-enabled bank partners. The revenue of the company is primarily comprised of fees paid by banks.
Read more on UPST →
